Psychiatry · Medical Literature
Efficacy of Adjunct PRObiotics as Compared to the Standard Care in Moderate Unipolar Depression Among Geriatric Patients: A Randomized Double-Blind Placebo-Controlled Pilot Multi-Center Trial (PRODG).
Abstract
To evaluate the efficacy of adjunct probiotic supplementation ( Lactobacillus helveticus and Bifidobacterium longum ) alongside standard care compared to placebo in older adults with moderate unipolar depression. A randomized, double-blind, placebo-controlled pilot trial was conducted at two tertiary centers. Fifty-eight participants (≥ 60 years) with moderate depression were randomized 1:1 to receive daily probiotics or a placebo for 12 weeks, alongside standard antidepressant care. They were followed up for another 12 weeks. The primary outcome was depression response (≥ 50% Montgomery-Åsberg Depression Rating Scale [MADRS] score reduction). Secondary outcomes included anxiety (General Anxiety Disorder 7-Item [GAD-7]), cognition, quality of life (WHOQOL-BREF), serum brain-derived neurotropic factor (BDNF), and gut microbiota profile. Mixed-effects models showed significant improvement over time in depressive symptoms (MADRS: F = 32.0, p 100, p 50% over 24 weeks. In this pilot PRODG trial, adjunct probiotics produced modest overall advantages for depressive and anxiety symptoms compared with placebo but did not enhance quality-of-life beyond usual improvement - both groups improved substantially, and trajectories over 24 weeks were largely parallel across follow-up.
Clinical relevance
In adults aged ≥60 years with moderate unipolar depression receiving standard antidepressant care, does adjunctive daily supplementation with Lactobacillus helveticus and Bifidobacterium longum improve depressive symptom response (≥50% MADRS score reduction) compared with placebo over 12 weeks of treatment and 12 weeks of follow-up? __SNAPSHOT__ {"studyDesign":"Randomized, double-blind, placebo-controlled, parallel-group, pilot multi-center trial (PRODG)","setting":"Two tertiary care hospitals in India: All India Institute of Medical Sciences (New Delhi) and National Institute of Mental Health and Neurosciences (Bengaluru); conducted 2023–2025","sampleSize":"n=58 (probiotic: 29, placebo: 29); target enrollment was n=80 — trial was underpowered relative to its original sample size target","population":"Adults ≥60 years with DSM-defined moderate unipolar major depressive disorder (single or recurrent episode), MADRS score 20–34 at baseline, receiving concurrent antidepressant therapy","intervention":"Daily oral probiotic containing Lactobacillus helveticus and Bifidobacterium longum (approximately 6 billion CFU/day per secondary reporting) added to standard antidepressant care for 12 weeks","comparator":"Matched placebo plus standard antidepressant care for 12 weeks","primaryOutcome":"Depression response defined as ≥50% reduction in MADRS score from baseline at 12 weeks","followUp":"12 weeks active treatment followed by 12 weeks observational follow-up (total 24 weeks)","fundingSource":"Not reported in available abstract/sources; conducted at two major Indian government-affiliated academic medical institutions"}
Key findings
Mixed-effects models across the full 24-week observation period demonstrated a robust main effect of time for depressive symptoms (MADRS: F=32.0, p 100, p 80% in both groups among those retained. Cognition outcomes were assessed but between-group results were not reported in the available abstract. Primary endpoint response rates (≥50% MADRS reduction) by treatment arm were not reported in available sources.
Practice implications
The PRODG trial establishes that adjunctive L. helveticus and B. longum supplementation is associated with modestly lower overall depressive and anxiety symptom burden compared with placebo in geriatric patients with moderate unipolar depression receiving concurrent antidepressants. However, the absence of a significant group × time interaction on the primary symptom measure means the trial did not demonstrate that probiotics accelerate or amplify improvement over time relative to placebo — a more clinically meaningful endpoint. The biological plausibility of the intervention is supported by significantly elevated serum BDNF and confirmed gut colonization of supplemented strains in the probiotic group, consistent with a gut-brain axis mechanism. The trial did not establish functional benefit: quality-of-life scores improved equivalently in both arms. Findings apply to older Indian adults (≥60 years) with moderate unipolar depression on active antidepressant therapy attending tertiary psychiatric centers; generalizability to non-Indian populations, primary care settings, patients with severe depression, bipolar disorder, significant cognitive impairment, or those not on antidepressants is not established. The primary response rate by arm (≥50% MADRS reduction) was not reported, making direct assessment of clinical magnitude impossible from the available abstract alone. The trial was also underpowered (58 of 80 planned participants enrolled) and suffered >50% attrition, both of which substantially limit confidence in estimates. Practice change is not supported at this stage; this is hypothesis-generating data requiring confirmation in a larger, adequately powered, ideally multi-national trial. Note: this summary is based on the published abstract and secondary reporting, as full-text data extraction was not available; exact primary endpoint response rates and full adverse event tables could not be independently verified. __LIMITATIONS__ Significantly underpowered: 58 of 80 planned participants enrolled, reducing ability to detect true between-group differences and inflating risk of both Type I and Type II error,Attrition rate exceeded 50% over 24 weeks, introducing substantial risk of attrition bias and compromising the integrity of repeated-measures analyses,Non-significant group × time interaction for the primary outcome (MADRS F=2.0, p=0.137) indicates that the probiotic group did not show a statistically distinguishable trajectory of improvement from placebo, undermining claims of differential efficacy over time,Primary endpoint response rates (≥50% MADRS reduction by arm) not reported in available abstract or secondary sources, precluding calculation of NNT,Heterogeneous antidepressant regimens administered at treating clinician's discretion represent a major confounder; escitalopram-equivalent dose significantly predicted MADRS outcomes, indicating antidepressant dose variation likely drove a meaningful portion of symptom change,Single-country, dual tertiary-center study conducted in India limits generalizability to other ethnic, socioeconomic, dietary, and healthcare-system contexts, particularly given the known influence of baseline microbiome composition on probiotic response,Specific dose, formulation, and CFU count of the probiotic product not fully reported in the abstract; strain-specific replication is therefore limited,Cognition outcomes assessed but between-group results not reported in the available abstract,Funding source not reported, preventing assessment of potential sponsorship bias,Pilot designation: the trial was explicitly designed to assess feasibility and preliminary efficacy, not to provide definitive evidence of benefit; conclusions must be interpreted accordingly,Blinding integrity (allocation concealment verification) not described in available abstract __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ The PRODG trial provides preliminary, hypothesis-generating evidence that adjunctive probiotic supplementation (L. helveticus and B. longum) produces modestly lower depressive and anxiety symptom scores compared with placebo in geriatric patients with moderate unipolar depression on standard antidepressant therapy, with a supportive biological signal (elevated BDNF, confirmed gut colonization). However, the absence of a significant group-by-time interaction, the failure to demonstrate quality-of-life benefit, >50% attrition, enrollment shortfall relative to target, heterogeneous antidepressant regimens, and single-country tertiary-center conduct collectively preclude practice change. Clinicians may reasonably discuss probiotics as a low-risk adjunct in interested patients but should await results of the planned larger confirmatory trial before considering routine recommendation.